Knowledge Centre

Yesterday, the government and Lilly announced a health innovation programme of up to £85m, delivered by Innovate UK, to demonstrate new weight management pathways in the community. The UK government will contribute up to £50m in new UK-wide investment through the Obesity Healthcare Goals programme, managed by Innovate UK, with up to £35m of grant funding coming from Lilly.

A structured approach to help local authorities help local authorities prepare for the Green Book option process, ultimately supporting council to design, appraise and fund capital-intensive Net Zero investments.

Join Ignite labs to build your fuel switching idea (e-fuels) for Industrial Decarbonisation. Any organisations working in e-fuels supply chain and keen to innovate, test their idea and embed design thinking into their products and processes are welcome to apply.

This Innovate UK Global Alliance Africa Strategic Learning Review offers a reflective and analytical overview of the project’s progress, insights and impact to date. It draws on stakeholder experience, programme data, learnings from events, and identifies what has worked and challenges overcome throughout the duration of the project.

Join innovators, growers, researchers, and technology developers for a full day of demonstrations, discussions, and collaboration focused on accelerating robotics adoption through real-world testbeds.

Join us to discover Innovate UK’s Innovation Exchange (iX); a national programme aimed at accelerating innovation by linking industry needs with pioneering solutions drawn from across industry sectors.

Bactobio is pioneering the discovery of novel antibiotics and fungicides by exploring the vast, uncharted world of uncultured microorganisms—bacteria that exist in soil but have never been studied in the lab.

Oxford-based Greywolf Therapeutics is developing new treatments for cancer patients who currently have limited immunotherapy options. With support from Innovate UK’s Biomedical Catalyst and Cancer Therapeutics programmes, the company is focusing on colorectal cancer, the UK’s fourth most common cancer and second leading cause of cancer-related death.

Sheffield-based MetalloBio, in partnership with the School of Science and Technology and Medical Technologies Innovation Facility at Nottingham Trent University (NTU), is developing a new class of antimicrobial agent using an innovative inorganic chemistry approach.